Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
40%
Ph early_phase_1
1
20%
Ph phase_4
1
20%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(1)
Other(2)

Detailed Status

unknown2
Recruiting1
Enrolling by invitation1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 41 (25.0%)

Trials by Status

unknown240%
recruiting120%
enrolling_by_invitation120%
completed120%

Recent Activity

1 active trials
Showing 5 of 5
enrolling_by_invitationearly_phase_1

Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)

NCT06499025
recruitingphase_2

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

NCT06316960
unknownphase_2

Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

NCT05638984
completed

An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome

NCT01400633
unknownphase_4

A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome

NCT02013102

Clinical Trials (5)

Showing 5 of 5 trials
NCT06499025Early Phase 1

Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)

Enrolling By Invitation
NCT06316960Phase 2

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Recruiting
NCT05638984Phase 2

Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

Unknown
NCT01400633

An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome

Completed
NCT02013102Phase 4

A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5